Novartis UK has today announced proposals for an internal change programme that will enable our teams to improve their offer to the NHS and patients. With an industry-leading pipeline of medicines that serve patients in different ways, the programme aims to future-proof the organisation, so it can fulfil its belief that nobody should have to wait for an extraordinary life.
Entitled Tomorrow Transformed, the programme proposes a series of internal structural changes within the Pharmaceuticals division that will ensure, in the ever-evolving world of healthcare, customers remain at the heart of the company’s operations. As part of this, employees will be supported with capability training, so they can continue to lead the way in building the right partnerships and collaborations for the benefit of patients and the healthcare system.
In reaching our ambition of better supporting patients, our people are our number one priority. Associates will shape the process through consultations that will begin in October, with the transformed structures expected to be in place by early 2021. While every effort will be made to redeploy, retrain and support all affected associates, it is expected that as a result of the proposed changes, there will be a slight reduction in headcount within the division. Novartis is committed to treating all associates sensitively, fairly and thoughtfully as the proposed new structure is consulted upon and implemented.